Aquestive Therapeutics: Poised for 200% Growth with Anaphylm, Cantor Predicts
Cantor Fitzgerald initiates coverage of Aquestive (AQST) with an Overweight rating, predicting 200% growth by 2025. This bullish outlook is driven by Anaphylm, a novel oral film for severe allergic reactions, potentially disrupting the epinephrine market.
Aquestive Therapeutics: Poised for 200% Growth with Anaphylm, Cantor Predicts Read More »